AgingResearch.News

Use this when the user asks a research question on the biology of aging, longevity interventions, age-related disease, or the people and companies of the field (for example: does rapamycin extend lifespan in people, what is known about senolytics for frailty, who works on epigenetic clocks). Not for personal medical advice, doses or symptoms. It answers from AgingResearch.News's own record of papers, trials, approvals, mouse lifespan results, human genetics, researchers and companies, and says when that record is thin. Returns an answer of at most about 350 words with numbered sources, each linked to its page, and the conversation's address. It spends one of the user's Ask questions for the day on their AgingResearch.News account. Pass conversation_id for a follow-up. If the answer takes longer than a call allows, the result says so: read it with get_ask_answer and its question_id.

Use this when the user asks how many drug and therapy programmes there are, or how a field's pipeline splits. Counts programmes grouped by stage, modality, target, hallmark, indication, the developer's country or the developer, with each group's count at each stage. Takes list_assets' filters: by=target with indication=obesity counts the targets of obesity programmes. An account whose plan includes drug and therapy programmes reads every record in full; others read an outline, as the site's asset pages show it.

Use this to find the type and key of what a question names (a drug, supplement or diet, a gene or protein, a biological process, a disease, a biomarker, an organism, a method or a hallmark of aging) before get_entity, list_claims or list_grants. Matches part of a name, a key or a known synonym, case-insensitive, most-studied first, with how many papers involve each. Pass a result's type and key to get_entity.

Use this when the user asks to follow a drug, gene, process, disease or other entity on AgingResearch.News, so its new papers reach them. Takes the type and key that find_entities or get_entity give. Following is saved to the user's account: new papers on it appear in For you and the daily follow email.

Use this when ask_arn or start_ultradeep said an answer is still being written, or the user wants it again: it reads that question's answer by the question_id they gave: the answer with its numbered sources once it is written, or where it stands while it is written. Waits up to 20 seconds for a short answer that is nearly done; an Ultradeep review takes several minutes.

Use this when the user asks about one drug or therapy programme by its name or any code name (ubx1325, UBX-1325, BMS-986278). Returns its developers, partners and licensors, targets, mechanism, modality, every indication with its stage and the trial or source behind it, its lifespan evidence and the news that names it. An account whose plan includes drug and therapy programmes reads every record in full; others read an outline, as the site's asset pages show it.

Use this when the user asks about one meeting from list_conferences, or what was presented there. Returns its organiser, site and every edition; with `edition`, that edition's abstracts worth reading, the most relevant first, each with its number, format and the paper it was later published as. An abstract is not a peer-reviewed paper. Read one in full with get_paper.

Use this for questions about one drug, supplement, gene, process or disease, such as: is there human evidence for this intervention; has the finding been replicated by independent labs; in which species; what trials test it and how many have posted no results; who funds the work and which companies are tied to it; what the newest papers on it report. Takes a type and key from find_entities (intervention rapamycin, disease sarcopenia). Returns the entity with the papers that involve it, newest first, and the role it plays in each. For an intervention, a gene or a process, `evidence` gives its evidence as structure, never as a grade: the species its findings reach and whether independent labs found the same there, the labs and countries behind them, the findings against, its trials and those with no results posted, its funders and its company ties. The counts are of the papers AgingResearch.News has read, not of all the literature. Not for personal medical advice or doses.

Use this when the user wants one paper in depth: what it did and found, in which species and how many subjects, its caveats, who wrote it and where they work. Takes a paper id such as MED-42823970 from another tool's results. Returns how it bears on aging, the language it was published in with its own-language title when that is not English, every author with ORCID iD and institutions, its full story (headline, body, why it matters, caveats) when published, the drugs, genes and processes it studies and its findings, and a link to the paper at its source. It does not replace the paper.

Use this when the user asks about one clinical trial by its registry number (NCT, ISRCTN, ChiCTR, CTRI, CTIS and the rest): its design, outcomes and dates, what changed and when, and which papers cite it. Returns the registry's summary, outcomes and dates, every change recorded and the papers that cite it. A record from the WHO ICTRP carries its attribution and the day WHO processed it, to show with it.

Use this when the user asks which drugs or therapies are in development against a target, a mechanism, a hallmark of aging or an age-related disease, who develops them and how far each has got. Lists drug and therapy programmes (assets), furthest stage first: each with its developers and partners, code names, modality, targets, mechanism, indications with the stage of each, hallmarks of aging and lifespan evidence. Narrow by target (a gene symbol such as GLP1R, or a process), mechanism words, modality, hallmark, indication, stage, the developer's country, an organisation or a name. Read one in full with get_asset; count them with count_pipeline. An account whose plan includes drug and therapy programmes reads every record in full; others read an outline, as the site's asset pages show it.

Use this when the user asks what has been found about a relation: does an intervention extend lifespan, and in which organisms; what lowers a biomarker; what acts on a process. Lists findings extracted from papers as subject, relation and object (for example rapamycin extends_lifespan in Mus musculus), with organism, conditions, effect size and the paper, newest first. Narrow by subject, object, relation, organism or paper. Check a finding that matters against its paper with get_paper. Not for personal medical advice.

Use this when the user asks which meetings on aging research and age-related disease are coming up, or which have just been held. The conference calendar: meetings still to come or on, soonest first, then recent ones, each edition with its dates, place and how many of its abstracts are held. Read one, and an edition's abstracts, with get_conference.

The sidebar's feed: For you or Top, as story cards.

Use this when the user asks what they follow on AgingResearch.News. Lists the drugs, genes, processes and saved searches their account follows, newest first, each with its page; an entity's id is the type:key that unfollow takes.

Use this when the user asks who funds work on a target, a drug, a process or a lab, how much and since when, or what a funder pays for in aging research. Lists research grants from NIH, the EU (CORDIS), UKRI and Wellcome that bear on aging, newest award first: title, funder, holder, investigators, amount, funded period, scheme and a link to the record. Narrow by an entity the title names (type:key, as find_entities gives), a funder or holder key, title words or award date. Other funders and private money are not here; for company financings use list_news.

Use this when the user asks about events in aging research and the longevity industry: company financings and deals, trial readouts, approvals and regulators, policy, conferences. One story per event, newest first, written by AgingResearch.News with a link to every outlet that covered it. Narrow by words, kind or date. Only news of this field; not for general, political or market news.

Use this when the user asks what is new: the latest papers in a field (mitochondrial dysfunction, immune aging, senolytics), of a study type such as randomised trials, on a body system, or by one author (author takes a name, or an author_id from get_paper), for example to shortlist a lab's journal club. Lists the newest papers AgingResearch.News has read, by the date they were added, with the same filters as search_papers and an optional words filter. For the papers that best answer a question, use search_papers.

Use this when the user asks about questions they asked AgingResearch.News (Ask) before. Lists their most recent conversations, newest first, each with its title and its address, where the answer and its sources are.

Use this when the user wants a readable round-up of recent findings: what happened this week in aging research, the notable results in a field, or a short list for a journal club. Lists the stories AgingResearch.News wrote about new papers, newest first, each checked against its paper: a plain-language headline, body, why it matters and caveats, with the paper. Narrow by category, body system, study type or publication date. Only the papers chosen for a story; for every paper on a question use search_papers.

Use this when the user asks about clinical trials on aging or an age-related condition: what is recruiting, what changed lately (a new status, a completion, results posted), which trials test a drug, or which companies run them. Lists trials from ClinicalTrials.gov that bear on human aging, newest registry update first: phase, status, sponsor, size, conditions, interventions and the latest change. Narrow by words, phase, recruitment status, focus, industry sponsor or update date. Only trials about aging, not every registered trial. Read one with get_trial.

Use this when the user asks to open AgingResearch.News or to see their feed, follows and recent questions in one place. Shows the newest stories (For you when the user is signed in, else Top), what they follow and their recent questions, with search.

The sidebar's search: topics and papers matching words, as cards.

Use this when the user asks what research has found on a question in the biology of aging or an age-related disease, often without the word aging: senescence and senolytics, epigenetic clocks, partial reprogramming, mitochondrial dysfunction, NAD+, inflammaging and immune aging, ovarian aging and menopause, neurodegeneration, cardiovascular and metabolic decline, sarcopenia, regeneration, and long-lived species such as naked mole rats and whales. Searches the titles and abstracts of every paper AgingResearch.News has read, best match first. Supports "quoted phrases", OR and -exclusions; narrow by study type, category, body system, link to aging, preprint status, author or the date it was added. By default only papers about aging. Each result gives its study type, how it bears on aging, its subjects and its story if one was published. The record is not all of PubMed: no match does not mean no study exists. Not for personal medical advice, symptoms or product recommendations. Read one in full with get_paper.

Use this when the user asks for a full review of the evidence on a research question in aging or longevity, beyond a short answer. Not for personal medical advice, doses or symptoms. It writes, over several minutes, a review in five sections: the bottom line, the evidence by kind of study, contradictions and gaps, how far it has got toward patients, and what would change the answer. It is started on the user's own AgingResearch.News account and counts against their plan's Ultradeep reviews. Returns at once with the address of the conversation where the review appears and a question_id: get_ask_answer says where it stands and gives the review once it is in.

Use this when the user asks to stop following a drug, gene, process or other entity on AgingResearch.News. Takes the type and key that list_follows, find_entities or get_entity give. Removes the follow from the user's account.